Abstract: The present invention provides an immunogenic composition comprising an antigen and a dendritic cell targeting component. A charged group is covalently attached to a dendritic cell ligand and is electrostatically associated with the dendritic cell targeting component.
Type:
Grant
Filed:
January 22, 2015
Date of Patent:
February 13, 2018
Assignee:
INNAVAC PTY LTD
Inventors:
David Charles Jackson, Weiguang Zeng, Brendon Yew Loong Chua
Abstract: This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a TLR2 moiety in solution, wherein the TLR2 moiety comprises a TLR2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the TLR2 moiety.
Type:
Grant
Filed:
September 22, 2011
Date of Patent:
June 13, 2017
Assignee:
INNAVAC PTY LTD
Inventors:
David Charles Jackson, Amabel Tan, Weiguang Zeng